Patents Assigned to GlaxoSmithKline Intellectual Property Development Limited
-
Patent number: 11945826Abstract: The present invention relates hydroxypyridoxazepine compounds, methods of making them, pharmaceutical compositions containing them and their use as Nrf2 activators. In particular, the invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, or a tautomer thereof, or a hydrate thereof.Type: GrantFiled: February 11, 2020Date of Patent: April 2, 2024Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventors: Mark Elban, Michal Pawel Glogowski, Michael Clinton Koetting, Brian Griffin Lawhorn, Jay M. Matthews, Jaclyn Renee Patterson
-
Publication number: 20240083896Abstract: Compounds of formula (I) are described, wherein each of the variable groups is as defined in the specification. Also described are pharmaceutical compositions containing a compound of formula (I), and uses of the compounds and pharmaceutical compositions for inhibiting Nav1.8 voltage-gated sodium channels and treating Nav1.8 mediated diseases, disorders, and conditions, such as pain and pain-associated diseases, disorders, and conditions and cardiovascular diseases, disorders, and conditions, such as atrial fibrillation.Type: ApplicationFiled: December 16, 2021Publication date: March 14, 2024Applicant: GlaxoSmithKline Intellectual Property Development LimitedInventors: Xiaoyang DONG, Mark Andrew ELBAN, Jie GUANG, Ming-Hsun HO, Tram H. HOANG, Joseph J. ROMANO, David Glenn WASHBURN
-
Publication number: 20240051972Abstract: The invention relates to compounds of Formula (I), (Ia), (Ib), (II) or (III), salts thereof, pharmaceutical compositions thereof, as well as therapeutic methods of treatment and prevention.Type: ApplicationFiled: August 31, 2022Publication date: February 15, 2024Applicants: GlaxoSmithKline Intellectual Property Development Limited, The University of North Carolina at Chapel Hill, ViiV Healthcare CompanyInventors: Martha DE LA ROSA, Richard M. DUNHAM, David MARGOLIS, Vincent Wing-Fai TAI, Jun TANG
-
Publication number: 20240025988Abstract: Provided herein are interleukin 7 (IL-7) binding proteins, pharmaceutical compositions and their use in the treatment or prevention of a disease or condition.Type: ApplicationFiled: September 5, 2023Publication date: January 25, 2024Applicant: GlaxoSmithKline Intellectual Property Development LimitedInventors: Gerben BOUMA, Edward Thomas COULSTOCK, David DIXON, Stephanie HOPLEY, Alan Peter LEWIS, Jessica Lynn NEISEN
-
Patent number: 11873310Abstract: The invention relates to compounds of Formula (I), (Ia), (Ib), (II) or (III), salts thereof, pharmaceutical compositions thereof, as well as therapeutic methods of treatment and prevention.Type: GrantFiled: August 6, 2021Date of Patent: January 16, 2024Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventors: Vincent Wing-Fai Tai, Jun Tang
-
Publication number: 20230416287Abstract: Provided are compounds and pharmaceutical compositions and uses thereof for inhibiting Nav1.8 voltage-gated sodium ion channels and treating Nav1.8 mediated diseases, such as pain and pain-associated diseases, and cardiovascular diseases.Type: ApplicationFiled: June 7, 2023Publication date: December 28, 2023Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITEDInventors: Jie GUANG, Jay M. MATTHEWS, Alan T. PRICE, Jared Troy SPLETSTOSER
-
Patent number: 11795474Abstract: The invention relates to retroviral producer cell comprising nucleic acid sequences encoding: gag and pol proteins; envelope protein or a functional substitute thereof; amplifiable selection marker; and the RNA genome of the retroviral vector particle, wherein said nucleic acid sequences are all integrated at a single locus within the retroviral producer cell genome. The invention also relates to nucleic acid vectors comprising a non-mammalian origin of replication and the ability to hold at least 25 kilobases (kb) of DNA, characterized in that said nucleic acid vector comprises retroviral nucleic acid sequences encoding: gag and pol proteins, and an env protein or a functional substitute thereof. The nucleic acid vector additionally comprises nucleic acid sequences encoding an amplifiable selection marker. The invention also relates to uses and methods using said nucleic acid vector in order to produce stable retroviral packaging and producer cell lines.Type: GrantFiled: April 18, 2018Date of Patent: October 24, 2023Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventor: Conrad Vink
-
Patent number: 11773078Abstract: This invention relates to novel compounds according to Formula (I) which are inhibitors of furin, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of fibrotic diseases, including pulmonary fibrosis, renal fibrosis, liver fibrosis, skin fibrosis, ocular fibrosis, cardiac fibrosis, and other miscellaneous fibrotic conditions. The disclosed compounds may also be useful for treating other furin-mediated conditions, including but not limited to, hypertension, cancer, infectious diseases, and genetic disorders (e.g., cystic fibrosis (CF)), and neurodegenerative disorders.Type: GrantFiled: May 10, 2019Date of Patent: October 3, 2023Assignee: Glaxosmithkline Intellectual Property Development LimitedInventors: Jeffrey Michael Axten, Mui Cheung, Michael P. Demartino, Huiping Amy Guan, Yan Hu, Aaron Bayne Miller, Donghui Qin, Chengde Wu, Zhiliu Zhang, Xiaojuan Lin
-
Publication number: 20230295313Abstract: The present invention relates generally to antibodies in the treatment of human disease and reduction of adverse events related thereto. More specifically, the present invention relates to the use of IL 1RAP (Interleukin-1 receptor accessory protein) binding proteins (including anti-IL 1RAP 0 antagonist antibodies) and their use as treatment and prevention of human disease.Type: ApplicationFiled: June 22, 2020Publication date: September 21, 2023Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITEDInventors: John G. Emery, Qi Fei, Shiyong Gong, Sanjay Kumar, Fang Ren, Teddy Yang, Hua Ying
-
Publication number: 20230279106Abstract: The present disclosure relates to compositions for treating CD96 mediated diseases, and related methods.Type: ApplicationFiled: September 2, 2022Publication date: September 7, 2023Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITEDInventors: Yan Y. DEGENHARDT, Jun GUAN, Kenneth William HANCE, Peter Joseph MORLEY
-
Patent number: 11697665Abstract: Disclosed herein are C-mannoside compounds, compositions thereof and their application as pharmaceuticals for the treatment of human disease. Methods of inhibition of FimH activity in a human subject are also provided for the treatment of diseases such as bacterial infection, Crohn's disease (CD) and Inflammatory Bowel Disease (IBD).Type: GrantFiled: July 9, 2021Date of Patent: July 11, 2023Assignees: Fimbrion Therapeutics, Inc., GlaxoSmithKline Intellectual Property Development LimitedInventors: Michael Joseph Bishop, Eugene L. Stewart, Katherine Louisa Widdowson, James Walter Janetka, Laurel Kathryn McGrane
-
Publication number: 20230192842Abstract: Chimeric antigen receptors (CARs) which include an antigen binding protein that binds to a discontinuous epitope on human claudin-3 comprising at least N38 and E153 of SEQ ID NO:13 are described. Also described herein includes polynucleotides encoding the antigen binding protein, the CARs, immune effector cells containing the CARs, pharmaceutical compositions containing the immune effector cells, and methods of treating cancer with the immune effector cells.Type: ApplicationFiled: September 22, 2022Publication date: June 22, 2023Applicant: GlaxoSmithKline Intellectual Property Development LimitedInventor: Thomas Southgate
-
Patent number: 11649238Abstract: The invention relates to compounds of formula (I) which are inhibitors of kinase activity, pharmaceutical formulations containing the compounds and their uses in treating and preventing viral infections and disorders caused or exacerbated by the viral infection wherein R1, R2, R3, R4a, R4b, R4c, R5, W, X, Y and Z are defined herein.Type: GrantFiled: January 15, 2019Date of Patent: May 16, 2023Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITEDInventors: Nicholas Paul Barton, Sophie Marie Bertrand, Kenneth David Down, Matthew Gray
-
Patent number: 11649289Abstract: The present invention provides methods for increasing expression of ICOS on an effector T cell comprising contacting said effector T cell with an anti-PD-1 antibody. The present invention also provides methods for decreasing expression of ICOS on a regulatory T cell comprising contacting said regulatory T cell with an anti-PD-1 antibody. The present invention provides methods for increasing sensitivity to an agent directed to ICOS in a human comprising administering to the human an anti-PD1 antibody. The present invention also provides methods of treating cancer in a human in need thereof comprising administering an anti-PD-1 antibody and an anti-ICOS antibody to said human, wherein the anti-PD-1 antibody increases T cell sensitivity to the ICOS antibody.Type: GrantFiled: August 3, 2017Date of Patent: May 16, 2023Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventors: Sabyasachi Bhattacharya, Paul M. Bojczuk, Heather L. Jackson, Mili Mandal, Hong Shi, Sapna Yadavilli, Niranjan Yanamandra
-
Patent number: 11643407Abstract: The present invention relates to indane compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 activators.Type: GrantFiled: May 16, 2019Date of Patent: May 9, 2023Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventor: Jeffrey K. Kerns
-
Publication number: 20230120185Abstract: Disclosed are compounds having the formula: wherein R1, R2, and R3 are as defined herein, and methods of making and using the same.Type: ApplicationFiled: September 27, 2022Publication date: April 20, 2023Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITEDInventors: Niall Andrew Anderson, Deepak Bandyopadhyay, Alain Daugan, Frederic G. Donche, Patrick M. Eidam, Nicolas Eric Faucher, Nicolas S. George, Philip Anthony Harris, Jae U. Jeong, Bryan W. King, Clark A. Sehon, Gemma Victoria White, David Duff Wisnoski
-
Publication number: 20230101987Abstract: The invention relates to substituted pyridine derivatives that are inhibitors of the activity of DNA methyltransferase 1 (DNMT1). The invention also relates to pharmaceutical compositions comprising such compounds and methods of using such compounds in the treatment of cancer, pre-cancerous syndromes, beta haemoglobinopathy disorders, and other diseases associated with inappropriate DNMT1 activity.Type: ApplicationFiled: October 14, 2022Publication date: March 30, 2023Applicant: GlaxoSmithKline Intellectual Property Development LimitedInventors: Andrew B. BENOWITZ, David T. Fosbenner, Bryan Wayne King, Stuart Paul Romeril
-
Patent number: 11613571Abstract: The present disclosure relates to compositions comprising antibody variants, for treating interleukin 5 (IL-5) mediated diseases, and related methods.Type: GrantFiled: May 21, 2019Date of Patent: March 28, 2023Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITEDInventors: Chika Akinseye, Tejinder Bhinder, Li Cui, Steven Grant, Laura Hook, Alan Peter Lewis, Martin Anibal Orecchia
-
Publication number: 20230071675Abstract: Disclosed are compounds having the formula: wherein q, r, s, A, B, C, RA1, RA2, RB1, RB2, RC1, RC2, R3, R4, R5, R6, R14, R15, R16, and R17, are as defined herein, or a tautomer thereof, or a salt, particularly a pharmaceutically acceptable salt, thereof.Type: ApplicationFiled: May 17, 2022Publication date: March 9, 2023Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITEDInventors: Adam Kenneth CHARNLEY, Michael G DARCY, Jason W. DODSON, Xiaoyang DONG, Terry V. HUGHES, Jianxing KANG, Lara LEISTER, Yiqian LIAN, Yue LI, John F. MEHLMANN, Neysa NEVINS, Joshi M. RAMANJULU, Joseph J. ROMANO, Gren Z. WANG, Guosen YE, Daohua ZHANG
-
Publication number: 20230051209Abstract: The present invention relates to a composition comprising bacteria of the Delftia genus, specifically a composition comprising Delftia tsuruhatensis as well as the bacteria itself for use in the prevention of malaria transmission and methods of using the compositions for reducing malaria and/or malaria parasite transmission.Type: ApplicationFiled: July 10, 2020Publication date: February 16, 2023Applicant: GlaxoSmithKline Intellectual Property Development LimitedInventors: Alfonso MENDOZA LOSANA, Janneth RODRIGUES